These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21282259)

  • 1. Anticoagulation in people with atrial fibrillation.
    Fang MC
    BMJ; 2011 Jan; 342():d530. PubMed ID: 21282259
    [No Abstract]   [Full Text] [Related]  

  • 2. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis.
    Lip GY
    Thromb Haemost; 2008 Jul; 100(1):11-3. PubMed ID: 18612530
    [No Abstract]   [Full Text] [Related]  

  • 3. [Which patients with atrial fibrillation need anticoagulation?].
    Despotovic SF; Siewe S; Keta A
    Rev Med Suisse; 2010 Sep; 6(264):1816-8, 1820. PubMed ID: 20964018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.
    Mant JW
    Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of atrial fibrillation burden in assessing thromboembolic risk.
    Zimetbaum P; Waks JW; Ellis ER; Glotzer TV; Passman RS
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1223-9. PubMed ID: 25516580
    [No Abstract]   [Full Text] [Related]  

  • 6. Anticoagulation in atrial fibrillation and flutter.
    Scholten MF; Thornton AS; Mekel JM; Koudstaal PJ; Jordaens LJ
    Europace; 2005 Sep; 7(5):492-9. PubMed ID: 16087116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anticoagulation in atrial fibrillation].
    Binggeli C; Brunckhorst CB
    Herz; 2008 Feb; 33(1):13-9. PubMed ID: 18273573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 9. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thromboembolic risk in atrial fibrillation: new clinical perspectives].
    Villani GQ; Andreoli AM; Villani M; Capucci A
    G Ital Cardiol (Rome); 2008 Oct; 9(10 Suppl 1):22S-26S. PubMed ID: 19195302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China.
    Hu D; Sun Y
    J Am Coll Cardiol; 2008 Sep; 52(10):865-8. PubMed ID: 18755352
    [No Abstract]   [Full Text] [Related]  

  • 12. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients.
    Lane DA; Lip GY
    Thromb Haemost; 2009 May; 101(5):802-5. PubMed ID: 19404530
    [No Abstract]   [Full Text] [Related]  

  • 13. Blood pressure. The forgotten factor in previous and recent studies regarding anticoagulation in atrial fibrillation.
    Kallistratos MS; Manolis AJ; Mancia G
    Int J Cardiol; 2013 Oct; 168(4):4434-5. PubMed ID: 23890867
    [No Abstract]   [Full Text] [Related]  

  • 14. The need for new oral anticoagulants in clinical practice.
    Hylek EM
    J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):605-9. PubMed ID: 19571764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial fibrillation--rate versus rhythm control.
    Manning WJ
    N Engl J Med; 2003 Mar; 348(13):1284-6; author reply 1284-6. PubMed ID: 12661569
    [No Abstract]   [Full Text] [Related]  

  • 16. [Are the CHADS(2) and CHA(2)DS(2)-VASc scales useful instruments to initiate anticoagulant medication?].
    Fernández-Bergés D; Félix-Redondo FJ; Consuegra-Sánchez L; Galán Montejano M
    Rev Clin Esp; 2012 Sep; 212(8):418-9. PubMed ID: 22534168
    [No Abstract]   [Full Text] [Related]  

  • 17. Ablation for atrial fibrillation: can we decrease thromboembolism without increasing the risk for bleeding?
    Asirvatham SJ
    Circulation; 2007 Nov; 116(22):2517-9. PubMed ID: 18040036
    [No Abstract]   [Full Text] [Related]  

  • 18. Anticoagulation for atrial fibrillation: underuse?
    Pechlaner C
    Am J Med; 2011 Jul; 124(7):e11; author reply e13. PubMed ID: 21683818
    [No Abstract]   [Full Text] [Related]  

  • 19. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk stratification tools for evaluating thromboembolic risk in atrial fibrillation].
    Ouardiri Y; Marti C; Carballo S; Garin N
    Rev Med Suisse; 2011 Feb; 7(280):313-6, 318-9. PubMed ID: 21381276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.